Pharma Industry News Update: 2 June 2017
Patient Centricity & Pharma’s Reputation Patient Centricity used to be a buzzword in that it was often mentioned but seldom practiced by pharma companies. A lot of progress has been made in the past years to achieve patient centricity, but not all drug companies have had much success. Unfortunately, that has had a negative impact on the industry’s reputation.
Top 10 Most Reputable Pharma Companies
According to “Friendly” Public Segment
[From pharmamkting.blogspot.com] Depending on who you ask, the drug industry’s reputation is at an all-time low (read, for example, “Pharma’s Rep Among Patient Groups Sinks to Near Historical Lows“) or an all-time high!
For example, if you determine the reputation of a pharma company measured by “the general public who are somewhat or very familiar with the company,” then that company’s reputation is likely to score much higher than if you asked the general public whose “familiarity” with the company is not a factor.
Such is the case with the latest Reputation Institute ranking, which was said to be based on the opinions of the “general public.” Later in the fine print of the PR, you learn what they measured are the attitudes of only a segment of the general public – those who are “familiar” with the companies.
- According to Edelman, 80% of People Think #Pharma Puts Profits Ahead of People
- Can You Trust Patient Rankings of #Pharma Corporate Reputation?
- Pharma Marketing Ethics & Corporate Reputation Compendium
What is patient-centricity… really?
Patient-centricity is a prominent buzzword but there is little consensus on the real meaning or the true purpose behind the engagement.
eyeforpharma has addressed, the WHAT, the WHY, and the HOW behind patient-centricity in their latest magazine:
- WHAT: We speak with AstraZeneca about how they have come to publish the first definition of patient-centricity, co-created with patients and carers
- WHY: Pfizer, Merck and GSK give us their perspectives on how being patient-centric will deliver BOTH patient and shareholder value
- HOW: We showcase some of the industry’s most impactful patient initiatives – this year’s eyeforpharma Award winners
With exclusive insights from the following industry leaders:
- Guy Yeoman, Vice President, Patient Centricity at AstraZeneca
- Andy Schmeltz, Senior Vice President, Patient & Health Impact at Pfizer
- Julie Gerberding, Executive Vice President, Strategic Communications, Global Public Policy, and Population Health at Merck
- Kate Knobil. Chief Medical Officer, Pharmaceuticals at GSK
- Rob Gallo, Head of Corporate Communications – Europe and Canada at Takeda
- Elizabeth Turcotte, Director, Patient Hub and UPL Lead at Bristol-Myers Squibb
- Don Obazanek, Public Affairs Manager at AbbVie
sponsored by eyeforpharma
Pharma v. PBMs v. Pharmacies
The “Three Stooges of Drug Price Lobbying!
[From www.nytimes.com] A civil war has broken out among the most powerful players in the pharmaceutical industry – including brand-name and generic drug makers, and even your local pharmacists – with each blaming others for the rising price of medicine.
“You remember that old photograph of the Three Stooges, their faces cracked sideways and they are pointing at each other?” asked Chester Davis Jr., the president of the Association for Accessible Medicines. “Everyone is doing the finger-pointing, when in fact there is a lot of blame to go around.”
Members of Congress have put forward a grab-bag of options, each of which would help or hurt different industry players (read “A Look at Major Drug-Pricing Proposals: The Good, The Bad, and The Defeated“).
Some address minor aspects, such as a bipartisan bill that would force brand-name drugmakers to hand over samples of their drugs to generic competitors. One would allow for the importing of cheaper drugs. Another would force pharmacy benefit managers to disclose more information about how they did business.
For now, it is a free-for-all.